简体中文English

KMT2A (MLL) (11q23) gene breakage probe reagent
Wholesale Price(RMB):

30006000330066003300660036007200

Product Code:R-0501253Ⅰ-01/R-0501253Ⅰ-02/R-0501253Ⅱ-01/R-0501253Ⅱ-02/R-0501253Ⅲ-01/R-0501253Ⅲ-02/R-0501253Ⅳ-01/R-0501253Ⅳ-02
Probe name:GSP KMT2A(Centromere)/ GSP KMT2A(Telomere)
Product Code:Type I (direct FISH method)/Type II (biotin-labeled indirect FISH method)/Type III (digoxigenin-labeled indirect FISH method)/Type IV (TSA-FISH method)
Registration Number:
Clinical Value

Acute myeloid leukemia (AML)

KMT2A (MLL) is located at 11q23, a region of common chromosomal abnormalities, including translocation insertions and deletions;

KMT2A gene abnormalities are seen in ML and LL, with an incidence of up to 85% in childhood B-ALL, and also in lymphomas; prognosis is poor, with a high risk of therapeutic failure;

Simple KMT2A breaks in AML suggest a prognosis of Moderate.


Acute lymphoblastic leukemia (ALL)

KMT2A (MLL) gene is located at 11q23, a region of common chromosomal abnormalities, including translocation insertions and deletions;

KMT2A gene abnormalities are seen in ML and LL, with up to an 85% prevalence in childhood B-ALL, and also in lymphoma; poor prognosis and high risk of treatment failure;

is a marker of ALL with the worst prognosis.